Experiments show promising results for a drug that could lead to a lasting treatment for millions of Americans with macular degeneration.
Researchers at the University of North Carolina School of Medicine today published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease.
“We believe we may have found an optimized treatment for macular degeneration,” said senior study author Sai Chavala, MD, director of the Laboratory for Retinal Rehabilitation and assistant professor of Ophthalmology and Cell Biology & Physiology at the UNC School of Medicine. “Our hope is that MDM2 inhibitors would reduce the treatment burden on both patients and physicians.”
The research appeared Sept. 9, 2013 in the Journal of Clinical Investigation.
As many as 11 million Americans have some form of macular degeneration, which is the most common cause of central vision loss in the western world. Those with the disease find many daily activities such as driving, reading and watching TV increasingly difficult.
Currently, the best available treatment for macular degeneration is an antibody called anti-VEGF that is injected into the eye. Patients must visit their doctor for a new injection every 4-8 weeks, adding up to significant time and cost.
“The idea is we’d like to have a long-lasting treatment so patients wouldn’t have to receive as many injections,” said Chavala. “That would reduce their overall risk of eye infections, and also potentially lower the economic burden of this condition by reducing treatment costs.” Chavala practices at the Kittner Eye Center at UNC Health Care in Chapel Hill and New Bern.
All patients with age-related macular degeneration start out with the “dry” form of the disease, which can cause blurred vision or blind spots. In about 20 percent of patients, the disease progresses to its “wet” form, in which abnormal blood vessels form in the eye and begin to leak fluid or blood, causing vision loss.
While anti-VEGF works by targeting the growth factors that lead to leaky blood vessels, MDM2 inhibitors target the abnormal blood vessels themselves causing them to regress — potentially leading to a lasting effect.
Chavala and his colleagues investigated the effects of MDM2 inhibitors in cell culture and in a mouse model of macular degeneration. They found that the drug abolishes the problematic blood vessels associated with wet macular degeneration by activating a protein known as p53. “p53 is a master regulator that determines if a cell lives or dies. By activating p53, we can initiate the cell death process in these abnormal blood vessels,” said Chavala.
The Latest on: Macular degeneration
- Do vitamin supplements prevent macular degeneration? on November 19, 2017 at 2:44 pm
Vitamin and mineral supplements won’t prevent the development of age-related macular degeneration. But there is some evidence taking supplements containing vitamin C, vitamin E and zinc may slow the progression of age-related macular degeneration in ... […]
- Risk of Age-related Macular Degeneration Drops in the Baby Boom Generation on November 19, 2017 at 7:41 am
Bottom Line: The risk of developing age-related macular degeneration is much less in the Baby Boom (1946-1964) and later generations than in earlier generations, for unclear reasons. Why The Research Is Interesting: Because of increased life expectancy and ... […]
- Baby boomers avoiding macular degeneration better than previous generations on November 17, 2017 at 5:54 am
FRIDAY, Nov. 17, 2017 -- Macular degeneration is a major cause of vision loss in older Americans. But new research shows that baby boomers are somehow avoiding the illness at higher rates than their parents did. Why the improvement? The researchers aren't ... […]
- Global Age-Related Macular Degeneration Epidemiology and Patient - KAIT Jonesboro, AR - Region 8 News, weather, sports on November 16, 2017 at 4:35 pm
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please ... […]
- Global Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2017 on November 16, 2017 at 3:21 pm
LONDON, Nov. 16, 2017 /PRNewswire/ -- Fore Pharma announced the results of its Age-Related Macular Degeneration patients study in a new report 'Global Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2017'. Download the full report ... […]
- A pleasant picture for baby boomers: Lower risk of macular degeneration on November 16, 2017 at 2:32 pm
Baby boomers should look at this good news: They have a 60 percent lower risk of developing age-related macular degeneration than the previous generation, according to a UW-Madison study of people in Beaver Dam. And the previous generation, born in 1925 to ... […]
- Study: Lower risk of macular degeneration for baby boomers on November 16, 2017 at 9:51 am
Today's Baby Boomers are less likely to develop macular degeneration than their parents and grandparents. That's according to a new study from the University of Wisconsin in Madison. Researchers looked at nearly 5,000 older adults in the 1980's and their ... […]
- Wet Macular Degeneration Market Will See Strong Expansion Through 2024 on November 7, 2017 at 10:05 pm
Macular degeneration is a weakening or collapsed working of the eyes’ macula. Macula is the small area on the retinal surface covered by the light-sensitive tissue lining which is blackish area of the eye. This part of the retina is responsible for ... […]
- Ask a Doctor: Can lasers improve my macular degeneration? on November 6, 2017 at 11:48 pm
Q: Can lasers improve my macular degeneration? A: Various laser therapies have been used in the past for wet age related macular degeneration. Though these laser therapies had some modest benefit, laser therapy is not considered first line therapy for most ... […]
via Google News and Bing News